Enanta Pharmaceuticals, Inc. (ENTA)
NASDAQ: ENTA · Real-Time Price · USD
12.01
-0.36 (-2.91%)
Oct 8, 2026, 11:11 AM EDT - Market open
Enanta Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Enanta Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $21.83. The average 1-year stock price forecast is 81.77% higher than the current stock price, while the lowest is $19 (+58.20%) and the highest is $32 (+166.44%).
Price Target: $21.83 (+81.77%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Enanta Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 | Sep '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 5 | 5 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 6 | 6 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $20 | Buy | Reiterates | $20 | +66.53% | Sep 22, 2026 |
Financial Forecast
Revenue This Year
64.00M
from 65.32M
Decreased by -2.03%
Revenue Next Year
63.74M
from 64.00M
Decreased by -0.41%
EPS This Year
-2.29
from -3.84
EPS Next Year
-2.37
from -2.29
EPS and Forward PE are based on non-GAAP adjusted numbers.